Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

PharmaEssentia’s Besremi receives FDA approval for ET

Sep 1, 2026, 9:05 AM

Read Full Article → PharmaEssentia’s Besremi receives FDA approval for ET

PharmaEssentia’s Besremi receives FDA approval for ET

Translate article text

Choose a language and wait for the translated text.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

PharmaEssentia’s Besremi receives FDA approval for ET | PharmaVoice